Enliven Therapeutics Inc (ELVN)

Finanzdaten der Enliven Therapeutics Inc-Aktie (ELVN)

Gewinn- und Verlustrechnung

Vierteljährlich

*Alle Zahlen in Millionen

Enddatum des Zeitraums	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31
Periodenlänge	3 Monate	3 Monate	3 Monate	3 Monate	3 Monate
Revenues	-	-	-	-	-
Operating Expenses	14.33% 25.99	22.73	24.25	20.13	16.42
Operating Income/Loss	14.33% -25.99	-22.73	-24.25	-20.13	-16.42
Nonoperating Income/Loss	3.27% 3.249	3.359	3.479	3.413	1.694
Income/Loss From Continuing Operations Before Tax	17.39% -22.74	-19.37	-20.77	-16.72	-14.72
Income/Loss From Continuing Operations After Tax	17.39% -22.74	-19.37	-20.77	-16.72	-14.72
Net Income/Loss	17.39% -22.74	-19.37	-20.77	-16.72	-14.72
Preferred Stock Dividends And Other Adjustments	-	-	-	-	-
Attributable To Noncontrolling Interest	-	-	-	-	-
Basic Average Shares	2,135% 42.05	1.8811	41.03	40.96	18.51
Diluted Average Shares	2,135% 42.05	1.8811	41.03	40.96	18.51
Basic Earnings Per Share	17.39% -0.54	-0.46	-0.51	-0.41	-0.80
Diluted Earnings Per Share	17.39% -0.54	-0.46	-0.51	-0.41	-0.80
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic	-	-	-	-	-